A Scoping Review of Hyaluronidase Use in Managing the Complications of Aesthetic Interventions

Background Hyaluronidase is used as an adjunct or main treatment to manage complications associated with cosmetic hyaluronic acid (HA) filler injections such as necrosis, blindness, hypersensitivity, delayed nodules, and poor aesthetic outcomes. Objective To systematically map the available evidence and identify the gaps in knowledge on the effectiveness of hyaluronidase use in managing the aesthetic complications associated with HA injections (vascular occlusion, blindness, nodules, delayed hypersensivity, granuloma, poor aesthetic outcome). Methods PubMed, Medline, Embase and Cochrane databases were used up to May 2022, to look for randomized clinical trials (RCTs), clinical trials, and retrospective case-control studies reporting on the use of hyaluronidase for managing the HA filler injection complications. Results The database search yielded 395 studies; of those 5 RCTs (all carried out in the USA) were selected (53 subjects), indicating the effectiveness of hyaluronidase for removal of un-complicated injected HA nodules (forearm, upper arm, or back skin). The follow-ups ranged from 14 days to 4 years. The amount of HA filler injected into each site varied from 0.2 to 0.4 mL. A dose dependent response was observed for most HA fillers. No major adverse reactions were reported. Overall, for removal of every 0.1 mL of HA filler they injected 1.25–37.5 units of hyaluronidase (single injections). When 3 consecutive weekly hyaluronidase injection was used much lower doses of 0.375–2.25 unit was utilised. There was no evidence in a form of RCTs, clinical trials, and retrospective case-control studies on the removal/reversal of HA injections in the facial skin, or management of over-corrections, inflammatory nodules, or tissue ischemia/necrosis associated with HA filler injection. Conclusion Based on studies on the forearm, upper arm and back skin, hyaluronidase can be used for the reversal of uncomplicated HA filler injection nodule. However, further adequately powered studies are warranted to establish the ideal treatment protocol/dose of hyaluronidase for reversal of HA filler injections in the facial region or management of complications associated with aesthetic HA injection. Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.


Introduction
Cross-linked hyaluronic acid (hyaluronan, HA) is a polysaccharide; the most used reversible filler in aesthetic medicine [1,2].HA is a highly hydrophilic molecule and an essential part of the extracellular matrix; it attracts water molecules and creates a gel-like substance even at low HA concentrations contributing to the viscoelastic properties of the skin [1,2].HA is a polysaccharide consisting of the repeating disaccharide D-glucuronic acid and N-Acetyl-Dglucosamine units.Each disaccharide unit can bind up to 15 molecules of water, allowing 1 g of hyaluronan to bind about 16 l of water [2].A high HA concentration, larger HA particle size, and increased number of cross-links all contribute to the increased durability of injectable HA fillers [1,2].Literature suggests that a high-molecular-weight HA has an anti-inflammatory behaviour, but a lowmolecular-weight HA is pro-inflammatory [1][2][3][4].
Early signs of HA induced vascular occlusion can be immediate with severe pain, or temporary blanching that often lasts for a few seconds due to disruption of blood flow primarily beyond the injection site.Subsequently, pain can increase followed by bluish-red skin discolourations, and finally if left untreated, progression to tissue necrosis is inevitable [8,9].

Hyaluronidases
Hyaluronidase dissolves HA and contributes to HA metabolism; it is an enzyme that is found in bacteria, such as in Staphylococcus aureus, in venoms of bees and snakes, and in some spices' testicular extracts [2]; Hyaluronidase cleaves HA's b1,4-glycosidic bonds.Woodward et.al. [9] suggested that 30 Units of hyaluronidase were needed to dissolve 0.1 mL of HA.
The management of HA injection vascular complications is often with infiltration of the entire area with large volume of hyaluronidase (1500 units, every 2-8 hours) [8].Hyaluronidase is administered directly at the HA injection site and along the course of the obstructed artery [10][11][12].Hyaluronidase injection is more likely to be successful when performed early (\ 4 h after injection of HA filler) [11].Delay in hyaluronidase administration can lead to tissue necrosis, scarring, blindness, or in rare cases cerebrovascular accidents [13,14].Visual loss occasionally occurred in patients who received HA injections in the glabella, nose, or forehead and often presenting with sudden ocular pain, ptosis, and ophthalmoplegia [15].Intraarterial injection of 1500 units of hyaluronidase into the facial artery or supratrochlear artery successfully treated tissue necrosis in cases of vascular embolism after facial HA filler injection [16].

Mechanism of Action and Therapeutic uses of Hyaluronidase
Hyaluronidases are a group of 6 mucolytic enzymes that break down the HA [23] (table 1).They can be derived from mammalian tissue (animal-derived) that is often associated with impurities and their potential for allergic reactions (24,25,26), or synthesized in-vitro in pure form using recombinant technology (rHuPH20) [24].
For this review we briefly summarise the clinical uses of hyaluronidase as follows.
A-Adjuvants to local anaesthesia to increase the duration and efficacy of anaesthesia in ophthalmic surgery [25], and other fields, as well as for chronic pain management and treatment of oedema or hematoma [23,25].
Hyaluronidase has been used for retrobulbar, peribulbar, and sub-Tenon's anaesthesia in eye surgery, as a 'spreading agent'.It reduces tissue oedema, periorbital oedema, and helps re-absorption of subcutaneous hematomas [2,27,28].It assists vitrectomy, that is the surgery of the retina, where vitreous requires removing (the gel-like substance that fills the middle portion of the eye) and replacing it with another solution [2] by degrading hyaluronic acid into disaccharide compounds and dissociating intercellular substance barrier to liquefy the vitreous [2].
Hyaluronidase has been used to increase the duration and efficacy of anaesthesia; it hydrolysis the HA, increasing connective tissue permeability and collectively leading to a faster anaesthetic effect and a greater anaesthetized surface [28].It has been used as an adjunct for inferior alveolar nerve blocks [29], intra-pulpal anaesthesia [30], or for craniectomy [31].Hyaluronidase may also reduce pain associated with anaesthetic injections by decreasing tissue tension [28].
B-Softening skin and related tissues, this includes topical treatment for phimosis (tight foreskin) [32], prevention of perineal trauma (laceration) during delivery [33], cervical ripening and induction of labour [34], treatment of oral submucous fibrosis [35], a premalignant condition caused by betel chewing and can lead to squamous cell carcinoma, and treatment of scleroderma-induced microstomia (limited mouth opening) [36].The sclerotic tissue found in systemic sclerosis is the result of the over-production of hyaluronan and collagen (types I, III, and VII) [36].
C-Acceleration of insulin exposure, hyaluronidase can be used in combination with rapid-acting insulin to accelerate insulin exposure, producing an ultra-rapid time-action profile with a faster onset and shorter duration of insulin action [37].
D-Treatment of carpal tunnel syndrome [38] E-Treatment of keloids and Hypertrophic scars [39,40] F-Off label use, Hyaluronidase is commonly used for managing over-corrections, asymmetry, lumps, and nodules developed after HA filler injection.It dissolves subcutaneous nodules and degrades HA correcting excessive quantities of injected HA fillers [41][42][43][44][45] and its duration of the activity is about 24-48 h in dermal tissues [10].It can be used at a high dose of 200 U or higher for treating skin necrosis associated with HA filler injections, caused by vascular occlusion and sometimes intra-arterially as a thrombolytic to treat eye/intracranial complications [16], and often without hypersensitivity test [23].

Safety and Hypersensitivity
Intra-dermal injection of 3 units of hyaluronidase to test for the development of a wheal has been suggested [46,47].Hyaluronidase is contraindicated in patients who developed hypersensitivity reactions to bee or wasp stings, owing to the presence of hyaluronidase in the venom [46,48,49].Relative contraindications are, the concurrent use of aspirin, corticosteroids, estrogens, furosemide, benzodiazepines, and phenytoin and anti-histamines.Above mentioned drugs may make tissues less sensitive to hyaluronidase and patients need a larger dose or repeated treatment [46,47,49].
The incidence of IgE-mediated Type I hypersensitivity is rare and estimated to be about 0.1%, unless large intravenous doses ([ 200000 units) are given, giving a much higher incidence of 33% [13,23].In case of severe allergy caused by exogenous hyaluronidase, the use of autologous serum may be considered in non-acute cases requiring accelerated removal of HA filler [2].Although rare, delayed allergic hypersensitivity reaction has also been reported after the treatment of granulomatous hyaluronic acid reaction [50].

Study Objectives
The objective of the present scoping review was to systematically map the available evidence and identify the gaps in our knowledge on the effectiveness of hyaluronidase use in managing the aesthetic complications associated with HA injections (vascular occlusion, blindness, nodules, delayed hypersensivity, granuloma, poor aesthetic outcome) and to report on the adverse effects associated with the use of hyaluronidase.

Methodology
For this scoping review, we used the PRIRMA extension for scoping reviews [51] and provided an overview or map of the evidence that was available.Search Strategy included the PubMed, Medline, Embase, and Cochrane Library databases.They were searched up to May 2022 for randomized clinical trials (RCTs), clinical trials, and retrospective case-control studies that assessed the efficacy of hyaluronidase in managing the complications of aesthetic HA injections.The search and MeSH terms are summarised in tables 2 and 3.The reference lists of all included studies and previous reviews were also searched for additional RCTs, clinical trials, and retrospective studies.We

Search Results
The database search yielded 395 studies (PubMed, Medline, Embase, and Cochrane Library databases).After reviewing the titles and abstracts, authors identified 5 RCTs 4 papers [52][53][54][55] (Table 4) that were relevant to this scoping review.Overall, 5 RCTs with 53 subjects reported the effectiveness of hyaluronidase for eliminating uncomplicated HA nodules.All studies were carried out in the USA.

Effectiveness of Hyaluronidase for Removal of Uncomplicated HA Nodules
The follow-ups for 5 clinical trials ranged from 14 days to 4 years.The amount of HA filler injected into each site varied from 0.2 to 0.4 mL per site.The injected hyaluronidase doses were 1.5-75 units per site.Overall, for removal of every 0.1 mL of HA filler the reviewed studies suggested an injection of 1.25-37.5 units of hyaluronidase (single injections).When 3 consecutive weekly hyaluronidase injection were used much lower doses of 0.375-2.25 unit was utilised.
Some mild post.inflammatory hyperpigmentation was observed, which resolved after 3 months.
*A score of 0-4 given as follows; 4 for maximal augmentation; 3 for moderately raised; 2 to a slightly raised bump; 1 to sites that were barely palpable at examination; and 0 to sites with no tactile trace of injected HA gel [52].
Overall, 5 RCTs with 53 subjects, confirmed the effectiveness of hyaluronidase for removal/reversal of un-complicated injected HA nodules in the forearm, upper arm and back skin and no major adverse reactions were reported.Vartanian et.al. [52] did not observe a significant difference between various doses of hyaluronidase (10, 20, or 30 units) at 4 months; this study didn't have a control group (without hyaluronidase injection) and some trends were also seen for the effectiveness of higher doses (30 units) at some time points (1-3 days, 8-14 days, and 29-60 days) [52].Juha ´sz et.al. [53] reported no significant difference in efficacy and rate of dissolution of all HA filler between 20 and 40 units of hyaluronidase.However, some trends were identified such as, the Restylane Silk was the slowest to dissolve over the 14-day period, contrary to the Belotero Balance, which was the fastest to degrade.
Alam et.al. [54] used 3 consecutive doses of hyaluronidase (1.5, 3, 9 Units) at 1, 2, and 3 weeks after HA filler injection, and observed that repeated weekly low-volume (1mL), low-doses of hyaluronidase (9 units) is effective, in particular for correction of minor irregularities.They noted a dose dependent response, with 9.0-unit hyaluronidase injection being more effective than 1.5-unit sites at 4 weeks and 4 months.
Zhang-Nunes et.al. [55] studied sites injected with Restylane-Lyft, Juve ´derm Ultra, and Juve ´derm Voluma for 4 years after hyaluronidase injection (2.5, 5, 10, or 20 units).Most of the changes for all HA filler injected sites occurred between the 30 min and 3 hr time points, after hyaluronidase injection, that continued gradual degradation up to day 3, with minimal change through week two.All 3 tested fillers showed a dose response, with Voluma being more pronounced.Juve ´derm Voluma required higher doses of hyaluronidase for dissolution (20 units), and Restylane appeared to respond to lower doses of hyaluronidase (2.5 units).
The present scoping review did not identify similar evidence for HA filler reversal in the facial region.

Effectiveness of Hyaluronidase for Management of Over-Corrections, Inflammatory Nodules, or Vascular Occlusions Following Aesthetic HA Filler Injections
Similarly, no evidence was found, in a form of RCTs, clinical trials, and retrospective case-control studies, on the management of over-corrections, inflammatory nodules, or tissue ischemia/necrosis associated with aesthetic HA filler injections; the available evidence was mainly retrospective case reports or case series.We have also listed the summary of 11 excluded studies [10,14,16,[56][57][58][59][60][61][62][63] in table 5.They were retrospective case series, with 5 cases or more, reporting on the use of hyaluronidase for managing aesthetic complications associated with aesthetic HA filler injection.This includes management of delayed onset nodules in tear trough augmentation [56], lip augmentation [59], delayed peri-orbital oedema [61,62], aesthetic overcorrection [10], Tyndall effect, and late nodules [10], late inflammatory cutaneous reactions in lip and tear trough regions [58], as well as management of skin necrosis [14,57], and vascular complications with [60,63] or without visual impairment [58].
The selected excluded studies used a wide range (2-2000 units) of hyaluronidase doses for treatment of delayed non-inflammatory HA nodules and over-corrections [10,56,59].Two studies [10,56] only used hyaluronidase and the other one [59] used triamcinolone (2-5 mg/ mL) in combination to hyaluronidase.Of particular interest was the study by Sadeghpour and colleagues [59], indicating higher incidence of delayed non-inflammatory HA nodules in HA fillers used Vycross technology.Two studies [61,62] reported on edema management of upper and lower eyelid and tear trough area that used 3-90 units of hyaluronidase per eyelid to remove the HA filler.Lower eyelid and tear rough area appears to be a challenging area for HA filler removal or corrections as reflected by the %80 need for HA filler reinjection and 10% need for blepharoplasty in this area [61].For upper eyelid only about 25% of patients needed HA filler reinjection [62].

Discussion
As explained earlier, based on the limited available evidence, a scoping review of the literature was conducted [51], suggesting a paucity of studies assessing the efficacy of hyaluronidase for the reversal of HA injections in the facial region.The findings were based on studies with small sample sizes and the experiments on the forearm, upper arm, and back skin [52][53][54][55].The applicability of findings generated from the study of arms (volar forearm or upper arm) or back skin for products designed for the face can be questionable [64,65].This is due to the varying thickness and elastic properties of the skin in different anatomical regions [65], which can be influenced by variations in components such as elastic network, fibrous collagen, and glycosaminoglycans [64][65][66].There were some variations in the degree of degradation of HA fillers after hyaluronidase injection that could be partly explained by the HA particle size, degree of crosslinking, different cross-linking technologies, and the amount of G-prime [2].We know from research [2] that higher HA concentration (such as JUV family), increased amount of G-prime (JUV X? and RES LYFT), larger HA particle size (such as RES LYFT), and increased number of cross-links (such as in JUV X and JUV X? using Hylacross technology) contribute to increased durability of injectable HA fillers requiring higher dose of hyaluronidase for dissolution.However, this effect was mainly seen in the in the first 2-3 weeks following hyaluronidase injections.
For this scoping review, we did not include animal studies, and studies that included other dermal fillers such as silicone [67] or calcium hydroxyapatite [68].Congress abstracts [69], case reports or case series reporting less than 5 cases [70] were excluded.A review of the selected excluded studies ([ = 5 subjects) highlighted some interesting findings, suggesting that hyaluronic acid injections into the glabellar region, nasal dorsum, and nasolabial fold near the eyes were the main sites with serious vascular occlusions and eye problems that needed urgent treatment [14,16,57,60]; some authors suggest the injection in these sites is not advised [71,72].Subsequent to vascular occlusion, patients often develop pain and characteristic reticulated erythema [57] in the areas supplied by facial artery [48,73,74].The most common initial ocular symptoms after HA injection are vision loss (%50) and orbital pain (%35) as well as headache and dizziness (%26) [75].
Different methods of hyaluronidase injection (localised or intra-atrial) have been used to manage the vascular occlusions such as skin necrosis, eye movement and visual impairment disorders, ptosis, as well as blindness or loss of visual field.In order to treat skin necrosis, some researchers used localised infiltration of hyaluronidase at the HA injection site [14,57] and some utilised intra-arterial injection of the either facial artery or supratrochlear artery [16].It appears that immediate [14] or early treatment (\2 days) [57] with localised hyaluronidase injection or intra-arterial injection [16] is associated with better outcome and full resolution of the skin necrosis.Zhang et.al. [16] described the ideal location for intra-arterial injection of hyaluronidase, as the junction of the lower margin of the mandible and the anterior margin of the masseter muscle.The facial artery diameter at this point is about 2.3 mm and less than the needle diameter (0.57-0.92 mm) [16].Similarly, for management of visual impairments, local injection of hyaluronidase at the HA injection site [63], retroocular hyaluronidase injection [63], or intraarterial injection [16,60,63] as well as aspirin and a form of steroids (methylprednisolone, prednisone, dexamethasone, or steroid pulse) have been used [75].However, recent systemic reviews [76,77] and a consensus opinion paper [78] suggested a limited success with retrobulbar hyaluronidase injection.Overall, there is no accepted universal protocol for the use of hyaluronidase in management of vascular complications caused by HA injections.Localised injections of 500-1500 units of hyaluronidase with hourly intervals as soon as vascular occlusion is detected has been suggested [8,79].It appears that lower doses (150-300 units), delayed injection, or localised infiltration of hyaluronidase [16,57] are less effective in management of vascular complications compared to intra-arterial injections of higher doses (1500 units) of hyaluronidase [16].Future studies are therefore, warranted to establish the ideal injection root (local or intra-arterial), the optimal dose of hyaluronidase, as well as additional treatments (i.e., antibiotics, glucocorticoids, other thrombolytics) for management of skin necrosis and visual impairment complications.
The HA slowly breaks down, binding to more water, maintaining the same volume progressively (isovolumetric degradation), contributing to the delayed occurrence of the oedema years after a successful HA treatment [74,80], which is the cause of concern for periocular HA injection [61,62].Based on 2 case series [61,62], we know that hyaluronidase maybe more successful in managing periorbital oedema in the upper than the lower eyelid.
There is no universal protocol for reversal of hyaluronic acid fillers and different brand of HA fillers present with various degrees of cross-linkage requiring different amount of hyaluronidase for dissolution [81].Hyaluronidase also dissolves native hyaluronic acid, but body will restore native HA in 15-20 hours [2].A limitation of the reviewed studies [52][53][54][55] is the use of subjective visual detection [54] or finger palpation using a 5-point scale system [52][53][54][55] that may not be able to detect and record subtle changes in palpation scores.Recently, there has been an increase in the use of ultrasound-guided methods [82,83] and ultrasound can be used in future studies to quantitatively assess the changes in the volume of HA filler over time.
There is a bit of dichotomy of the RTC trial designs and typical use of HA fillers.HA fillers is almost always injected below the skin in real clinical situations and sometimes over the bone.However, studies typically follow intradermal injection depth of HA (intradermal), followed by injection of hyaluronidase intra-lesionally.The failed dissolution of HA filler following multiple hyaluronidase injections, can to be caused by incorrect depth of injection.If fascial structures or muscles lie between the site of HA filler and the site of hyaluronidase hyaluronidase injection, dissolution is dramatically reduced, especially the HA filler exists in a large bolus.Withing this context, the use of ultrasound-guided methods [82,83] can be a good adjunct to locate the filler and assess quantitatively HA filler degradation after hyaluronidase injection.
The study by Vartanian et.al. [52] lacked a third group without any post-injection to assess the changes post HA injection and compare it to saline and hyaluronidase injections.They recommended a small dose of hyaluronidase equivalent to 5-10 U (0.1-0.2 mL of drug at 50 U/mL) to be injected initially to avoid an allergic reaction, 2 weeks after HA injection.Juha ´sz et.al. [53] also reported that lower concentrations (20 Units) of hyaluronidase were just as effective as higher concentrations (40 Units) in the removal of injected HA filler.Repeated weekly low-volume (0.1 mL) and low-doses of hyaluronidase (9 units) seem to be effective, in particular for correction of minor irregularities [54].This reduced the risk hypersensitivity and major changes in the affected area.
Another limitation is that the 0.2-0.4mL of injected HA filler that was used in 4 studies is very small and not representative of the volumes used when aesthetic practitioners use HA filler.These small volumes (0.2-0.4 mL) may be easily cleared by intrinsic enzymes, and therefore future studies may need to study the reversal of larger volumes of injected HA filler.Non-significant differences in the rate of degradation of different HA fillers [52,53], and different hyaluronidase doses can also be due to the small sample sizes in the 4 studies and future studies may benefit from larger sample sizes.
Alam et.al. [54] introduced the scalping concept with injections of small amount (0.1 mL) of low dose hyaluronidase (1.5-9 units) to achieve the desired effect.A treat to effect concept has therefore been suggested for elective removal of HA fillers with injection intervals of 2 weeks [13].Heydenrych et.al. [79] recommended an intralesional injections of 4-40 IU per 0.1 mL of injected HA filler [79].This all bears similarity to the findings of the 5 reviewed RCTs in this systemic review, which was 1.25-37.5 units of hyaluronidase (single injections) per 0.1 mL of injected HA filler.As suggested by Jones et al. [84] injection of 10 units of hyaluronidase for removal of every 0.1 mL of HA filler appears to be a safe starting point and can be repeated every 2 week to achieve the desired effect.
Overall, comparison between the 5 RCTs that assessed the efficacy of hyaluronidase was difficult as they used different formulations of HA filler or hyaluronidase, and HA filler brands may not react similarly to different hyaluronidases [81].In addition, there were different time intervals and protocols; however, it was evident that hyaluronidase was effective in reversal/removal of uncomplicated HA fillers located at the forearm, upper arm, and back skin.Further studies with larger sample sizes are warranted to establish the ideal treatment protocol/dose for reversal of facial HA injections or management of complications associated with aesthetic HA injection.

Table 1
Different forms of hyaluronidase currently available in the market

Table 2
Keyword search and MeSH terms used for PubMed search for the present scoping review.

Table 3
Keyword search and MeSH terms used for Ovid medline for the present scoping review Hyaluronic Acid or Hyaluronoglucosaminidase or HA filler* or cosmetic techniq* or dermal filler*).mp.[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] RCT or Randomi#ed clinical trial* or clinical trial* or retrospective stud* or Case.Control stud* or Case control Stud*).mp.[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 18. Skin diseases, viral/ 19.Skin diseases, bacterial/ 20.Skin.mp.and connective tissue diseases/[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 21.Skin diseases, eczematous/ 22. Skin diseases, Papulosquamous/ 23.Skin diseases, vascular/ 24.Ecchymosis/ 25.Ischemic stroke/ 26.Edema/ 27.Intracranial Embolism.mp.and Thrombosis/[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 28.Embolism.mp.and Thrombosis/[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 29.Intracranial embolism/ 30.Embolism/ 31.Blindness/ 32.Visual acuity/ 33.(adverse effect* or nodule* or papule* or mass* or lump* or bump* or induration* or granuloma* or granulation tissue* or foreign bod* or hypersensitivit* or swelling* or inflammation* or thrombosis or ischemia or embolism* or vascular embolism* or vascular occlusion* or necrosis or blindness or dermatosis or adverse event* or complication*).mp.[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 34.7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 35.Hyaluronoglucosaminidase/ 36.Thrombolytic therapy/ 37. (Hyaluronidase or HYAL or Hylenex or Hydase or Vitrase or Wydase or Hyalase).mp.[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]

Table 4
The summary of the findings of the included studies in the present scoping review

Table 5
List of the selected excluded studies and their summary findings